MA55088A - Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire - Google Patents

Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire

Info

Publication number
MA55088A
MA55088A MA055088A MA55088A MA55088A MA 55088 A MA55088 A MA 55088A MA 055088 A MA055088 A MA 055088A MA 55088 A MA55088 A MA 55088A MA 55088 A MA55088 A MA 55088A
Authority
MA
Morocco
Prior art keywords
cancer therapy
immune checkpoint
checkpoint inhibitor
benzene compound
alkynyl benzene
Prior art date
Application number
MA055088A
Other languages
English (en)
Inventor
Hiroshi Hirai
Kazuaki Matsuoka
Kazuhiko Yonekura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA55088A publication Critical patent/MA55088A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA055088A 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire MA55088A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JP2019112619 2019-06-18

Publications (1)

Publication Number Publication Date
MA55088A true MA55088A (fr) 2022-01-05

Family

ID=72239799

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055088A MA55088A (fr) 2019-02-28 2020-02-28 Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
MA055091A MA55091A (fr) 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055091A MA55091A (fr) 2019-02-28 2020-02-28 Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab

Country Status (8)

Country Link
US (2) US20220184082A1 (fr)
EP (2) EP3932425A4 (fr)
JP (4) JPWO2020175704A1 (fr)
KR (2) KR20210130774A (fr)
AU (2) AU2020228514A1 (fr)
MA (2) MA55088A (fr)
TW (2) TW202039507A (fr)
WO (2) WO2020175697A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CA3094431C (fr) 2018-03-19 2023-06-27 Taiho Pharmaceutical Co., Ltd. Composition pharmaceutique comprenant du sulfate d'alkyle de sodium

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫
EP3424505A4 (fr) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes

Also Published As

Publication number Publication date
AU2020228514A1 (en) 2021-10-07
US20220125793A1 (en) 2022-04-28
EP3932427A1 (fr) 2022-01-05
TW202045182A (zh) 2020-12-16
US20220184082A1 (en) 2022-06-16
EP3932425A1 (fr) 2022-01-05
KR20210131387A (ko) 2021-11-02
MA55091A (fr) 2022-01-05
JP2023096156A (ja) 2023-07-06
JP2023112136A (ja) 2023-08-10
EP3932427A4 (fr) 2022-12-07
JPWO2020175704A1 (fr) 2020-09-03
JPWO2020175697A1 (fr) 2020-09-03
EP3932425A4 (fr) 2022-12-07
KR20210130774A (ko) 2021-11-01
TW202039507A (zh) 2020-11-01
AU2020229714A1 (en) 2021-10-07
WO2020175697A1 (fr) 2020-09-03
WO2020175704A1 (fr) 2020-09-03

Similar Documents

Publication Publication Date Title
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
MA49047A (fr) Composés inhibiteurs d'ask1 et utilisations associées
MA55088A (fr) Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
CO2021008681A2 (es) Inhibidor de 15-pgdh
CY1123871T1 (el) Ανταγωνιστες ιντεγκρινης
SG11202112103WA (en) Blockchain transaction comprising runnable code for hash-based verification
UA42369S (uk) Комп'ютер
CO2021009688A2 (es) Mezcla fungicida
ECSP20009753A (es) Combinaciones herbicidas sinérgicas
ZA201904876B (en) Combinations of a h3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof
GB2574209B (en) Controlling Threats on a Computer System by Searching for Matching Events on other Endpoints
IL264909A (en) Software for managing rehabilitation files
FR3082781B1 (fr) Pneumatique comprenant un composite piezoelectrique
CL2019001859A1 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
LT3758662T (lt) Vikšrinis laiptinis kopiklis
IL279000A (en) Treatment with AGI-134 together with a checkpoint inhibitor for the treatment of solid cancerous tumors
ES1245289Y (es) Brazo auxiliar de rotacion de valvulas cardiacas artificiales y llave de rotacion de valvulas cardiacas artificiales, que comprende un brazo auxiliar de rotacion
UA39199S (uk) Набір елементів для трансформаційної гри-тренінгу «философия денег»
UA140951U (uk) Розчин для обробки нафтової свердловини
CL2023001863S1 (es) Autoinyector portátil .
UA42058S (uk) Молоток слюсарний
UA41136S (uk) Підошва «9.11»
DK4065282T3 (da) Slidbeskyttelseselement til en findelingsindretning
DK4065281T3 (da) Slidbeskyttelseselement til en findelingsindretning
CL2021000059S1 (es) Batería. (divisional solicitud 202000517)